The FTC’s case against POM Wonderful was nominally about pomegranate juice. Its actual significance, for every healthcare practice making any kind of health claim today, is the substantiation standard the case confirmed. If your marketing says “clinically proven,” “scientifically backed,” “evidence-based,” or any variant, the POM Wonderful standard is what the FTC will apply to determine whether your evidence file actually supports the claim.
Most healthcare practices using this language do not have the evidence on file to meet the standard. This post walks through what the standard actually requires, why it applies to clinics the same way it applied to a beverage company, and what compliant substantiation-carrying language looks like in practice.
What POM Wonderful actually established
POM Wonderful marketed pomegranate juice and related products with claims that the juice could treat, prevent, or reduce the risk of specific conditions - heart disease, prostate cancer, and erectile dysfunction among them. The FTC challenged the claims. POM defended on the basis that it had funded studies supporting them.
The FTC’s position, upheld in subsequent litigation, was that the studies POM relied on did not meet the evidentiary bar required for the specific claims. The case established several things that have shaped health-claim enforcement ever since:
- Disease-specific claims require the evidentiary standard typically associated with FDA drug approval - adequate and well-controlled human clinical studies.
- Funded studies are not automatically disqualified, but the study design must meet the same rigor the claim would require from any source.
- “Proven” or similar language carries the full substantiation weight - even if the underlying claim is technically hedged.
What “competent and reliable scientific evidence” actually means
The phrase is a defined FTC term and means something specific: tests, analyses, research, or studies that:
- Have been conducted and evaluated in an objective manner.
- Were conducted by persons qualified to do so by appropriate training and experience in the relevant area of science.
- Used generally-accepted procedures in the relevant scientific field to yield accurate and reliable results.
For disease or condition claims specifically, this typically means well-designed randomized controlled trials - adequate sample size, appropriate controls, blinding, pre-registered endpoints, statistical analysis consistent with the field, and published peer-reviewed results. Single small studies, case series, anecdotal reports, and “most users report” data do not meet the bar.
The bar is claim-specific
One of the most important and commonly-missed aspects: the bar is calibrated to the specific claim being made. A claim that a treatment “may support cellular health” requires less evidentiary weight than a claim that the treatment “treats rheumatoid arthritis.” The mistake most clinics make is running specific-disease claims on general-science evidence.
The prior-substantiation requirement
The FTC requires “prior substantiation” - meaning the evidence must exist before the claim is made, not gathered afterward in response to a letter. Clinics making aggressive claims and expecting to assemble the evidence file “if we ever get asked” are already in violation.
The FTC’s administrative interpretation of this: if you are asked to produce your substantiation and cannot produce it on request - or you can only produce post-hoc assembly of studies that do not meet the scientific bar - you were making unsubstantiated claims from the moment the claims were published.
What healthcare marketing typically does wrong
The gap between typical healthcare marketing language and actual FTC-compliant substantiation is enormous. Here are the most common mistakes we see in practice audits.
Mistake 1: “Clinically proven” without the trial
The phrase “clinically proven” means something specific: adequate and well-controlled clinical trials with published results. Using it to describe a treatment based on mechanism-of-action studies, a few case reports, or the general scientific literature on a broader ingredient category is the single most common substantiation failure in healthcare marketing.
Mistake 2: Borrowing the evidence base from other products
Claim: “our IV formulation has been shown to improve immune function.” Evidence cited: studies on individual vitamins at specific doses in specific populations - none of which were on the specific IV formulation marketed. The borrowed-evidence shortcut fails the FTC bar because the substantiation has to be for the specific product marketed.
Mistake 3: Confusing regulatory approval with efficacy substantiation
FDA clearance or approval is not the same as FTC-compliant substantiation for a specific claim. A device can be FDA-cleared and still have unsupported efficacy claims in its marketing if the claims extend beyond what the clearance was based on. The two regulatory regimes are independent.
Mistake 4: “Studies show” without citation
Unattributed “studies show” claims create an implicit citation that the clinic often cannot back up. The FTC treats this as a claim about the underlying evidence base. If the studies do not exist or do not support the specific claim, it is a deceptive representation regardless of whether anyone asked to see them.
Mistake 5: Substantiation by testimonial
Testimonials are not substantiation. A hundred patients saying they felt better after a treatment does not substantiate an efficacy claim about the treatment. The FTC reads testimonials under the Endorsement Guides, and substantiation under the competent-and-reliable standard - they are separate regulatory requirements, and testimonials never cure a substantiation gap.
What compliant language actually looks like
Compliant substantiation-carrying language involves trade-offs between marketing force and legal defensibility. The compliant versions are less punchy but genuinely achievable.
Instead of “clinically proven to work”
Use: “Clinical studies of this [medication class / treatment category] in patients with [condition] have shown [specific published endpoint]. Individual patient outcomes depend on candidacy and adherence.” The key move is referring to the medication or treatment category’s evidence base rather than claiming your specific practice has its own clinical trials.
Instead of “scientifically backed”
Use: “Our protocol is based on the current clinical literature on [broader field]; we regularly review new publications and update our protocol accordingly.” This accurately describes a protocol informed by evidence without implying a specific substantiation claim about outcomes.
Instead of “proven to [outcome]”
Use: “Many of our patients experience [benefit]; individual outcomes vary based on [factors].” If you need to cite evidence, cite it specifically: “A 2024 randomized trial of [protocol] in patients with [condition] showed [specific outcome] compared to [comparator].”
Instead of “studies show”
Cite the specific study. “A 68-week randomized trial of semaglutide in patients with obesity showed average weight loss of approximately 15% of starting body weight (Wilding et al., NEJM 2021).” The named citation signals genuine substantiation and is actually more persuasive than the vague “studies show.”
The cheat code for compliant substantiation-carrying language is specificity. “Clinically proven” is risky; “a 2023 trial of X in Y patients showed Z” is both compliant and more convincing to anyone reading carefully. The reason “clinically proven” exists as marketing shorthand is that it replaces specificity with a shortcut. The shortcut is what the FTC targets.
Building a substantiation file
Practices with aggressive health claims should maintain a substantiation file - a document that inventories each objective claim, the evidence supporting it, and the specific studies relied on. This is good practice even without a regulator asking.
What the file should contain
- Every objective health claim made across your marketing, identified by surface (website page, ad, social post).
- For each claim: the specific evidence relied upon, with citations.
- An assessment of whether each piece of evidence meets the competent-and-reliable standard for the specific claim.
- Dates - when the claim was first published, and when the substantiation was compiled (prior-substantiation evidence).
- The attorney who reviewed, if any.
When to involve your attorney
Any claim that could be read as a disease-treatment claim needs attorney review. The substantiation analysis is genuinely technical and requires someone with healthcare regulatory experience to evaluate whether the evidence is sufficient for the specific claim. Do not rely on internal assessment alone for disease-specific claims.
Frequently asked questions
Does this apply to wellness claims, not just disease claims?
Yes, though the evidence bar is calibrated to the claim. “Supports immune function” requires substantiation but not the same level as “prevents flu.” The bar tracks the specificity and severity of the claim.
Can I use animal studies or lab studies for substantiation?
Not for human-outcome claims. Animal and in vitro studies can support mechanism-of-action claims but not claims about human clinical outcomes. Using animal studies to substantiate human efficacy claims is a specific FTC enforcement pattern.
What about “traditional use” claims?
Traditional-use framing (“traditionally used to support X”) has narrow FTC allowances in the dietary supplement context under specific DSHEA-related rules. It does not apply to healthcare practices offering treatments. Don’t import supplement-industry marketing conventions into service-practice marketing.
How long should I keep substantiation files?
At minimum, as long as the claim is being made, plus the applicable statute of limitations for FTC action (typically three years, sometimes longer depending on facts). Most practices keep the file indefinitely given the low storage cost.
Do other agencies use the same standard?
Similar standards are used by state AGs under consumer protection law, by the National Advertising Division in self-regulatory review, and by the FDA in some overlapping contexts. The FTC standard is the most frequently applied to healthcare marketing, but the principles are consistent across agencies.
What about AI-generated marketing copy?
AI-generated copy often includes confident health claims without the evidence base. This is the pattern that turns AI writing tools into a compliance liability for healthcare practices - the copy reads persuasive but fails substantiation review. Any AI-generated copy making objective health claims needs substantiation before it goes live.